RxIndia
Loading clinical data...
Loading clinical data...
Verified clinical guidelines and emergency management protocols.
| Procedure/Action | Primary Care | Secondary/Tertiary Care |
|---|---|---|
| Recognition (qSOFA, SIRS) |
✅
|
✅
|
|
SEPSIS SIX Bundle
|
✅
|
✅
|
| IV access & fluid bolus |
✅
|
✅
|
| First dose antibiotics |
✅
|
✅
|
| Blood glucose management |
✅
|
✅
|
| Lactate measurement |
⚠️ (POC if available)
|
✅
|
| Blood cultures |
⚠️ (if available)
|
✅
|
| Vasopressors |
❌
|
✅
|
| Central venous access |
❌
|
✅
|
| Mechanical ventilation |
❌
|
✅
|
| Renal replacement therapy |
❌
|
✅
|
| Source control procedures |
❌
|
✅
|
| Milestone | Target Time |
|---|---|
| Recognize sepsis |
Immediate
|
|
Complete SEPSIS SIX
|
≤ 1 HOUR
|
| Start fluid resuscitation |
≤ 15 min
|
|
Administer antibiotics
|
≤ 1 HOUR
|
| Reassess after fluids |
Every 250-500 mL
|
| Re-measure lactate |
Within 6 hours
|
| Term | Definition |
|---|---|
|
Sepsis
|
Life-threatening organ dysfunction caused by dysregulated host response to infection |
|
Operationally: Suspected infection + SOFA score increase ≥ 2
|
|
|
Septic Shock
|
Sepsis + Vasopressor required to maintain MAP ≥ 65 mmHg + Lactate > 2 mmol/L despite adequate fluid resuscitation
|
|
qSOFA
|
Quick bedside screening tool (NOT diagnostic, but prognostic) |
| Criterion | Finding | Points |
|---|---|---|
|
Respiratory Rate
|
≥ 22/min | 1 |
|
Altered Mentation
|
GCS < 15 | 1 |
|
Systolic BP
|
≤ 100 mmHg | 1 |
| qSOFA Score | Interpretation |
|---|---|
|
0-1
|
Low risk (does NOT rule out sepsis) |
|
≥ 2
|
High risk – urgent action needed
|
| Criterion | Abnormal Value |
|---|---|
| Temperature | > 38°C or < 36°C |
| Heart Rate | > 90 bpm |
| Respiratory Rate | > 20/min |
| WBC Count | > 12,000 or < 4,000/mm³ (if available) |
|
SIRS ≥ 2 + Suspected Infection
|
Possible Sepsis → Act Immediately
|
| # | Give | Details | Done? |
|---|---|---|---|
| 1 |
OXYGEN
|
Target SpO₂ ≥ 94%; start with mask/cannula |
☐
|
| 2 |
IV FLUIDS
|
Crystalloid (NS or RL) 500 mL bolus; repeat up to 30 mL/kg |
☐
|
| 3 |
ANTIBIOTICS
|
Broad-spectrum IV within 1 hour (see table below) |
☐
|
| # | Take | Details | Done? |
|---|---|---|---|
| 4 |
BLOOD CULTURES
|
If available; do NOT delay antibiotics |
☐
|
| 5 |
LACTATE
|
POC lactate if available; otherwise note clinical perfusion |
☐
|
| 6 |
URINE OUTPUT
|
Insert catheter if possible; measure hourly |
☐
|
| Rank | Source | Clinical Clues | Common Pathogens (India) |
|---|---|---|---|
| 1 |
Respiratory
|
Cough, sputum, crackles, hypoxia | S. pneumoniae, Klebsiella, H. influenzae, TB |
| 2 |
Urinary
|
Dysuria, flank pain, CVA tenderness | E. coli (high ESBL), Klebsiella, Enterococcus |
| 3 |
Abdominal
|
Pain, tenderness, distension | E. coli, Klebsiella, Bacteroides, Enterococcus |
| 4 |
Skin/Soft Tissue
|
Cellulitis, abscess, crepitus | Staphylococcus (MRSA 25-40%), Streptococcus |
| 5 |
CNS
|
Headache, neck stiffness, altered sensorium | S. pneumoniae, N. meningitidis, TB |
| 6 |
Tropical Infections
|
Travel, monsoon, endemic area | Dengue, Malaria, Scrub typhus, Leptospirosis, Enteric fever |
| Check | Source | Done? |
|---|---|---|
| Chest auscultation / percussion | Pneumonia |
☐
|
| Urine appearance / dipstick | UTI |
☐
|
| Abdominal examination | Intra-abdominal |
☐
|
| Skin examination (entire body) | Soft tissue infection |
☐
|
| IV sites, catheter sites | Device-related |
☐
|
| Neck stiffness, Kernig's sign | Meningitis |
☐
|
| Eschar (painless black scab) | Scrub typhus |
☐
|
| Jaundice + fever | Leptospirosis, Malaria, Hepatitis |
☐
|
| Splenomegaly | Malaria, Enteric fever, Kala-azar |
☐
|
| Recent travel / monsoon exposure | Tropical infections |
☐
|
| Step | Action | Details |
|---|---|---|
| 1 | Choose fluid |
Ringer's Lactate (preferred) or Normal Saline
|
| 2 | Initial bolus |
500 mL over 15-30 minutes
|
| 3 | Reassess | BP, HR, capillary refill, urine output |
| 4 | Repeat |
Up to 30 mL/kg total in first 3 hours
|
| 5 | Watch for overload | Crackles, rising JVP, worsening SpO₂ |
| Patient Weight | 30 mL/kg Volume |
|---|---|
|
40 kg
|
1200 mL
|
|
50 kg
|
1500 mL
|
|
60 kg
|
1800 mL
|
|
70 kg
|
2100 mL
|
|
80 kg
|
2400 mL
|
| Condition | Approach |
|---|---|
| Known heart failure | Smaller boluses (250 mL); watch for overload |
| Elderly (> 70 years) | Smaller boluses; frequent reassessment |
| Renal failure on dialysis | Very cautious; may need early transfer |
| Dengue shock | Judicious fluids (see dengue protocol) |
| Pathogen | Resistance Pattern in India | Implication |
|---|---|---|
|
E. coli / Klebsiella
|
ESBL: 60-80% in hospitals; 40-60% in community | Ceftriaxone often fails; need Pip-Taz or Carbapenem |
|
Klebsiella
|
Carbapenem resistance (CRE): 30-50% in some ICUs | May need Colistin/Polymyxin B |
|
Staphylococcus aureus
|
MRSA: 25-50% in hospitals | Need Vancomycin/Teicoplanin for serious infections |
|
Pseudomonas
|
MDR: 30-40% in ICUs | Need combination therapy |
|
Acinetobacter
|
Extensively drug-resistant in many ICUs | Often needs Colistin |
|
S. pneumoniae
|
Penicillin resistance: 2-5% (lower than West) | Ceftriaxone usually effective |
|
Salmonella Typhi
|
Fluoroquinolone resistance: 80-90% | Ceftriaxone or Azithromycin |
| Suspected Source | First-Line (Primary Care) | Dose | Alternative |
|---|---|---|---|
|
Unknown source
|
Ceftriaxone + Metronidazole |
2g IV + 500mg IV
|
Amoxicillin-Clavulanate 1.2g IV |
|
Pneumonia (Community-Acquired)
|
Ceftriaxone + Azithromycin |
2g IV + 500mg IV
|
Amoxicillin-Clavulanate 1.2g IV + Azithromycin |
|
UTI / Pyelonephritis
|
Ceftriaxone |
2g IV
|
Amikacin 15 mg/kg IV (single dose) |
|
Abdominal / Biliary
|
Ceftriaxone + Metronidazole |
2g IV + 500mg IV
|
Amoxicillin-Clavulanate 1.2g IV |
|
Skin / Soft Tissue
|
Ceftriaxone + Clindamycin |
2g IV + 600mg IV
|
Amoxicillin-Clavulanate 1.2g IV |
|
Suspected Meningitis
|
Ceftriaxone |
2g IV STAT
|
— (transfer urgently) |
|
Suspected Enteric Fever
|
Ceftriaxone |
2g IV
|
Azithromycin 1g IV/PO |
|
Suspected Scrub Typhus
|
Doxycycline |
100mg IV/PO
|
Azithromycin 500mg IV |
|
Suspected Leptospirosis
|
Ceftriaxone |
2g IV
|
Doxycycline 100mg IV |
| Note |
|---|
|
Do NOT wait for investigations to give first antibiotic dose
|
|
Ceftriaxone is the most practical first-line at primary level – covers many pathogens
|
|
Add Metronidazole if abdominal source suspected (anaerobic coverage)
|
|
Add Clindamycin for soft tissue infections (toxin suppression, anaerobic coverage)
|
|
Doxycycline is critical for scrub typhus – consider in fever with eschar, especially post-monsoon
|
|
Document exact time of antibiotic administration
|
|
Transfer patient – definitive antibiotic therapy will be at higher centre
|
| ⛔ Avoid Empirically | Reason |
|---|---|
| Oral antibiotics in sepsis | Unreliable absorption in shock |
| Fluoroquinolones alone for UTI | High resistance in India (80%+) |
| Cephalosporins alone for severe UTI in hospitalized patient | High ESBL rates |
| Aminoglycosides as monotherapy | Not sufficient as sole agent |
| RBS | Action |
|---|---|
|
< 70 mg/dL
|
25-50 mL of 25% Dextrose IV; recheck |
|
70-180 mg/dL
|
No intervention |
|
> 180 mg/dL
|
Avoid dextrose fluids; will need insulin at higher centre |
| SpO₂ | Action |
|---|---|
|
≥ 94%
|
No supplemental O₂ needed |
|
90-94%
|
Nasal cannula 2-4 L/min |
|
< 90%
|
Face mask 6-10 L/min; consider non-rebreather |
| ⛔ Do NOT | Reason |
|---|---|
| Delay antibiotics for cultures | Each hour delay increases mortality |
| Start vasopressors | Requires ICU monitoring |
| Give steroids | Reserved for refractory shock at ICU |
| Delay transfer for investigations | Stabilise and transfer |
| Give excessive fluids without reassessing | Risk of pulmonary edema |
| Indication | Urgency |
|---|---|
| All patients with suspected sepsis |
URGENT
|
| Septic shock (hypotensive despite fluids) |
IMMEDIATE
|
| Respiratory failure (SpO₂ < 90% on O₂) |
IMMEDIATE
|
| Altered mental status |
IMMEDIATE
|
| Lactate > 4 mmol/L |
IMMEDIATE
|
| Source requiring surgery/drainage |
IMMEDIATE
|
| Item | Done? |
|---|---|
| SEPSIS SIX initiated/completed |
☐
|
| IV access × 2 secured |
☐
|
| Fluid volume given documented |
☐
|
| Antibiotic given – drug and time documented |
☐
|
| Blood glucose checked |
☐
|
| Vital signs documented |
☐
|
| Suspected source documented |
☐
|
| Allergies documented |
☐
|
| Receiving hospital pre-alerted |
☐
|
| Information | Why Critical |
|---|---|
| Time of recognition | Tracking bundle compliance |
| Antibiotic given (drug, dose, time) | Avoid re-dosing; plan next doses |
| Fluid volume given | Guide ongoing resuscitation |
| Current BP and MAP | Vasopressor need |
| Suspected source | Guide investigations and surgery |
| Response to fluids | Fluid responsiveness |
| Action | Target Time |
|---|---|
| Primary survey (ABCDE) |
0-5 min
|
| Confirm SEPSIS SIX completed (or complete if not done) |
≤ 1 hour
|
| Measure lactate |
≤ 15 min
|
| Blood cultures (2 sets) |
Before antibiotics (don't delay > 45 min)
|
| Antibiotics (escalate if needed) |
≤ 1 hour
|
| Vasopressor if MAP < 65 despite fluids |
ASAP
|
| Element | Target | Done? |
|---|---|---|
| Measure lactate |
≤ 1 hr
|
☐
|
| Blood cultures before antibiotics |
≤ 45 min
|
☐
|
| Broad-spectrum antibiotics |
≤ 1 hr
|
☐
|
| 30 mL/kg crystalloid if hypotensive or lactate ≥ 4 |
Begin ≤ 1 hr
|
☐
|
| Vasopressors if MAP < 65 during/after fluids |
ASAP
|
☐
|
| System | Parameter | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|---|
|
Respiration
|
PaO₂/FiO₂ |
≥ 400
|
< 400
|
< 300
|
< 200 + support
|
< 100 + support
|
|
Coagulation
|
Platelets (×10³) |
≥ 150
|
< 150
|
< 100
|
< 50
|
< 20
|
|
Liver
|
Bilirubin (mg/dL) |
< 1.2
|
1.2-1.9
|
2.0-5.9
|
6.0-11.9
|
> 12
|
|
Cardiovascular
|
MAP / Vasopressors |
MAP ≥ 70
|
MAP < 70
|
Dopa ≤ 5 or Dobu
|
Dopa > 5 or NE/Epi ≤ 0.1
|
Dopa > 15 or NE/Epi > 0.1
|
|
CNS
|
GCS | 15 |
13-14
|
10-12
|
6-9
|
< 6
|
|
Renal
|
Creatinine / UOP |
< 1.2
|
1.2-1.9
|
2.0-3.4
|
3.5-4.9 or < 500 mL/d
|
> 5 or < 200 mL/d
|
| Investigation | Purpose | Timing |
|---|---|---|
|
Blood cultures (×2 sets)
|
Identify pathogen |
Before antibiotics
|
|
Lactate
|
Tissue perfusion |
Immediately; repeat q2-4h
|
|
CBC
|
WBC, platelets |
Immediately
|
|
RFT (Creatinine, BUN, electrolytes)
|
AKI, electrolyte disturbance |
Immediately
|
|
LFT (Bilirubin, ALT, AST)
|
Hepatic dysfunction |
Immediately
|
|
Coagulation (PT, INR, aPTT)
|
DIC |
Immediately
|
|
ABG / VBG
|
Acidosis, oxygenation |
Immediately
|
|
Procalcitonin
|
Bacterial infection marker |
If available
|
| Suspicion | Investigation |
|---|---|
|
Malaria
|
Peripheral smear + Rapid antigen test (RDT) |
|
Dengue
|
NS1 antigen (day 1-5), IgM (day 5+), platelet count |
|
Scrub Typhus
|
IgM ELISA, Weil-Felix (less reliable) |
|
Leptospirosis
|
IgM ELISA, MAT |
|
Enteric Fever
|
Blood culture (gold standard), Widal (limited utility) |
|
Tuberculosis
|
Sputum AFB, Gene Xpert, CBNAAT |
|
HIV
|
Rapid antibody test (with consent) |
| Principle | Details |
|---|---|
|
Obtain cultures BEFORE antibiotics
|
But don't delay antibiotics > 45 min |
|
Start empiric broad-spectrum
|
Narrow once cultures available |
|
Know your local antibiogram
|
Hospital-specific resistance patterns |
|
De-escalate at 48-72 hours
|
Based on culture results and clinical response |
|
Duration: shorter is better
|
5-7 days for most infections if responding |
|
Avoid carbapenems when possible
|
Reserve for confirmed ESBL/serious infections |
| Condition | Likely Pathogens (India) | Empiric Regimen | Duration |
|---|---|---|---|
|
CAP – Ward
|
S. pneumoniae, H. influenzae, Klebsiella, Atypicals | Ceftriaxone 2g IV q24h + Azithromycin 500mg IV q24h |
5-7 days
|
|
CAP – ICU (no Pseudomonas risk)
|
Same + Legionella | Ceftriaxone 2g IV q24h + Azithromycin 500mg IV q24h OR Levofloxacin 750mg IV |
7 days
|
|
CAP – ICU (Pseudomonas risk)
|
Add Pseudomonas | Piperacillin-Tazobactam 4.5g IV q6h + Levofloxacin 750mg IV q24h |
7 days
|
|
HAP (non-severe, early onset)
|
S. aureus, Enterobacteriaceae | Piperacillin-Tazobactam 4.5g IV q6h |
7 days
|
|
HAP/VAP (severe or late onset)
|
Pseudomonas, Acinetobacter, MRSA, ESBL producers | Meropenem 1g IV q8h + Vancomycin 15-20mg/kg q8-12h ± Colistin |
7-8 days
|
|
VAP with MDR risk
|
MDR GNB, Acinetobacter | Meropenem 1g q8h + Colistin 9 MU load then 4.5 MU q12h + Vancomycin |
7-8 days
|
|
Aspiration Pneumonia
|
Anaerobes, oral flora | Piperacillin-Tazobactam 4.5g IV q6h OR Ceftriaxone + Metronidazole |
7 days
|
| Condition | Likely Pathogens (India) | Empiric Regimen | Duration |
|---|---|---|---|
|
Uncomplicated UTI (outpatient)
|
E. coli (40-60% ESBL in community) | Nitrofurantoin 100mg BD OR Fosfomycin 3g single dose |
5 days / single
|
|
Complicated UTI / Pyelonephritis (community onset)
|
E. coli, Klebsiella (60%+ ESBL) | Piperacillin-Tazobactam 4.5g IV q6h OR Ertapenem 1g IV q24h |
7-10 days
|
|
Healthcare-associated UTI / Catheter-associated
|
ESBL producers, Pseudomonas, Enterococcus | Meropenem 1g IV q8h (if critically ill) OR Pip-Taz 4.5g q6h |
7 days
|
|
Urosepsis (critically ill)
|
ESBL, Pseudomonas, possible CRE | Meropenem 1g IV q8h ± Amikacin 15mg/kg q24h |
7-10 days
|
| Condition | Likely Pathogens | Empiric Regimen | Duration |
|---|---|---|---|
|
Community-acquired (mild-moderate)
|
E. coli, Klebsiella, Bacteroides, Enterococcus | Ceftriaxone 2g IV q24h + Metronidazole 500mg IV q8h |
4-7 days (source controlled)
|
|
Community-acquired (severe / septic)
|
Same + higher ESBL risk | Piperacillin-Tazobactam 4.5g IV q6h |
4-7 days
|
|
Healthcare-associated / Post-operative
|
ESBL, Pseudomonas, Enterococcus, Candida | Meropenem 1g IV q8h + Vancomycin (if Enterococcus concern) ± Fluconazole |
4-7 days
|
|
Biliary Sepsis
|
E. coli, Klebsiella, Enterococcus | Piperacillin-Tazobactam 4.5g IV q6h |
4-7 days + source control
|
|
Tertiary Peritonitis / MDR risk
|
CRE, MDR Pseudomonas, Candida | Meropenem + Colistin + Fluconazole/Echinocandin |
Based on cultures
|
| Condition | Likely Pathogens | Empiric Regimen | Duration |
|---|---|---|---|
|
Cellulitis (non-purulent)
|
Streptococcus, MSSA | Ceftriaxone 2g IV q24h |
5-7 days
|
|
Cellulitis (purulent / abscess)
|
MRSA (25-40% in India) | Ceftriaxone 2g + Clindamycin 600mg IV q8h OR Vancomycin |
5-7 days + drainage
|
|
Diabetic foot – Mild
|
Streptococcus, Staphylococcus | Amoxicillin-Clavulanate 1.2g IV q8h |
7-14 days
|
|
Diabetic foot – Moderate/Severe
|
MRSA, Pseudomonas, Anaerobes, ESBL | Piperacillin-Tazobactam 4.5g q6h + Vancomycin OR Meropenem + Vancomycin |
14-21 days
|
|
Necrotizing Fasciitis
|
Mixed aerobic/anaerobic, GAS, Clostridium | Meropenem 1g q8h + Vancomycin + Clindamycin 900mg q8h |
Until debridement complete + 7-14 days
|
|
Fournier's Gangrene
|
Mixed flora | Meropenem + Vancomycin + Clindamycin |
Urgent surgery + antibiotics
|
| Condition | Likely Pathogens | Empiric Regimen | Duration |
|---|---|---|---|
|
Community Bacterial Meningitis (adult)
|
S. pneumoniae, N. meningitidis | Ceftriaxone 2g IV q12h + Vancomycin 15-20mg/kg q8-12h + Dexamethasone |
10-14 days
|
|
Community Meningitis (> 50 yrs / immunocompromised)
|
Add Listeria | Add Ampicillin 2g IV q4h to above |
10-21 days
|
|
Healthcare-associated Meningitis
|
Staphylococcus, GNB, Pseudomonas | Meropenem 2g IV q8h + Vancomycin |
14-21 days
|
|
Brain Abscess
|
Streptococcus, Staphylococcus, Anaerobes, GNB | Ceftriaxone 2g q12h + Metronidazole + Vancomycin |
4-8 weeks
|
|
TB Meningitis
|
M. tuberculosis | ATT (HRZE) + Dexamethasone |
9-12 months
|
| Condition | Likely Pathogen | Empiric Regimen | Notes |
|---|---|---|---|
|
Scrub Typhus
|
Orientia tsutsugamushi | Doxycycline 100mg IV/PO q12h | Continue until afebrile × 3 days; total 7-14 days |
| OR Azithromycin 500mg q24h (if pregnant/child) | |||
|
Leptospirosis
|
Leptospira spp. | Ceftriaxone 2g IV q24h OR Penicillin G 1.5 MU IV q6h | 7 days |
| Doxycycline 100mg BD for mild cases | |||
|
Enteric Fever
|
S. Typhi (FQ-resistant 80%+) | Ceftriaxone 2g IV q24h OR Azithromycin 1g then 500mg q24h | 10-14 days |
|
Severe Malaria
|
P. falciparum | IV Artesunate 2.4 mg/kg at 0, 12, 24h then q24h | Switch to oral ACT when able |
|
Dengue with Warning Signs
|
Dengue virus | Supportive care; judicious IV fluids | No antibiotics unless bacterial co-infection |
|
Melioidosis
|
B. pseudomallei | Meropenem 1g q8h OR Ceftazidime 2g q8h | 2+ weeks IV, then oral TMP-SMX × 3-6 months |
| Condition | Likely Pathogens | Empiric Regimen | Duration |
|---|---|---|---|
|
Community-onset bacteremia (unknown source)
|
E. coli, S. aureus, Streptococcus | Piperacillin-Tazobactam 4.5g q6h OR Ceftriaxone 2g + Metronidazole |
Based on source
|
|
Healthcare-associated bacteremia
|
MRSA, ESBL, Pseudomonas | Meropenem 1g q8h + Vancomycin |
Based on source
|
|
Catheter-related BSI
|
CoNS, S. aureus (MRSA), GNB, Candida | Vancomycin 15-20mg/kg q8-12h ± Piperacillin-Tazobactam |
Remove catheter; 7-14 days
|
|
S. aureus bacteremia
|
MSSA or MRSA | Cloxacillin 2g q4h (MSSA) OR Vancomycin (MRSA) |
Minimum 14 days (longer if complicated)
|
|
Candidemia
|
Candida spp. | Echinocandin (Caspofungin/Micafungin/Anidulafungin) |
14 days after first negative culture
|
| Condition | Regimen | Notes |
|---|---|---|
|
Low-risk neutropenic fever
|
Amoxicillin-Clavulanate + Ciprofloxacin (oral) | Only if MASCC ≥ 21, outpatient capable |
|
High-risk neutropenic fever
|
Meropenem 1g IV q8h OR Piperacillin-Tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h | Monotherapy usually sufficient |
|
Add Vancomycin if:
|
Catheter infection, skin/soft tissue, hypotension, MRSA colonization | |
|
Add Antifungal if:
|
Persistent fever > 4-7 days despite antibiotics | Caspofungin or Liposomal Amphotericin B |
| Situation | Adjustment |
|---|---|
|
CrCl < 30 mL/min
|
Reduce carbapenem dose; avoid aminoglycosides or dose-adjust |
|
Hemodialysis
|
Give antibiotics post-HD; adjust dosing |
|
ESBL confirmed on culture
|
De-escalate to Ertapenem (if susceptible) or continue Meropenem |
|
CRE (Carbapenem-resistant)
|
Add Colistin 9 MU load → 4.5 MU q12h OR Polymyxin B 1.5-2.5 mg/kg/day divided ± Tigecycline (100mg load → 50mg q12h) ± Aminoglycoside |
|
MDR Acinetobacter
|
Colistin + Meropenem (high dose 2g q8h) OR Colistin + Tigecycline |
|
VRE (Vancomycin-resistant Enterococcus)
|
Linezolid 600mg IV/PO q12h OR Daptomycin (not for pneumonia) |
| Timing | Action |
|---|---|
|
24-48 hours
|
Review culture results |
|
48-72 hours
|
Narrow antibiotic spectrum based on culture and sensitivity |
|
Day 5-7
|
Assess for stopping antibiotics (procalcitonin may guide) |
| De-escalation Example | From | To |
|---|---|---|
| ESBL E. coli UTI sensitive to Pip-Taz | Meropenem | Piperacillin-Tazobactam |
| MSSA bacteremia | Vancomycin | Cloxacillin 2g IV q4h |
| Pneumococcal pneumonia | Broad-spectrum | Ceftriaxone alone (or Penicillin if sensitive) |
| Risk Factor |
|---|
| Prolonged ICU stay > 7 days |
| Total parenteral nutrition |
| Broad-spectrum antibiotics > 7 days |
| Central venous catheter |
| Recent abdominal surgery |
| Candida colonization at multiple sites |
| Hemodialysis |
| Immunosuppression |
| Scenario | Drug | Dose |
|---|---|---|
|
Suspected invasive candidiasis (stable)
|
Fluconazole |
800mg load → 400mg IV q24h
|
|
Critically ill / Prior azole / Unknown Candida
|
Echinocandin preferred | |
| Caspofungin |
70mg load → 50mg IV q24h
|
|
| Micafungin |
100mg IV q24h
|
|
| Anidulafungin |
200mg load → 100mg IV q24h
|
|
|
CNS candidiasis
|
Liposomal Amphotericin B |
5 mg/kg/day
|
|
Mucormycosis
|
Liposomal Amphotericin B |
5-10 mg/kg/day
|
| Indication |
|---|
| MAP < 65 mmHg despite 30 mL/kg crystalloid |
| MAP < 65 mmHg during fluid resuscitation with poor perfusion |
| Lactate > 4 mmol/L with hypotension |
| Drug | Dose Range | Role |
|---|---|---|
|
Norepinephrine
|
0.1-1+ μg/kg/min
|
FIRST-LINE
|
|
Vasopressin
|
0.03-0.04 U/min (fixed)
|
Second-line (add to NE)
|
|
Epinephrine
|
0.05-1 μg/kg/min
|
Third-line or cardiac dysfunction |
|
Dopamine
|
—
|
⛔ AVOID (more arrhythmias)
|
| Step | Action | Target |
|---|---|---|
| 1 | Start Norepinephrine 0.1 μg/kg/min | MAP ≥ 65 |
| 2 | Titrate NE up to 0.5 μg/kg/min | MAP ≥ 65 |
| 3 | Add Vasopressin 0.03 U/min | MAP ≥ 65 |
| 4 | Further increase NE | MAP ≥ 65 |
| 5 | Add Epinephrine OR Hydrocortisone | MAP ≥ 65 |
| Preparation | Concentration |
|---|---|
| 4 mg in 50 mL NS/D5W |
80 μg/mL
|
| 8 mg in 50 mL NS/D5W |
160 μg/mL
|
| Weight (kg) | 0.1 μg/kg/min (mL/hr) [80 μg/mL] | 0.3 μg/kg/min | 0.5 μg/kg/min |
|---|---|---|---|
| 60 | 4.5 | 13.5 | 22.5 |
| 70 | 5.25 | 15.75 | 26.25 |
| 80 | 6 | 18 | 30 |
| Indication |
|---|
| Septic shock refractory to fluids AND vasopressors |
| Norepinephrine ≥ 0.25 μg/kg/min for ≥ 4 hours |
| Drug | Dose | Duration |
|---|---|---|
|
Hydrocortisone
|
50 mg IV q6h OR 200 mg/day continuous infusion
|
7 days or until shock resolved
|
| Source | Intervention | Timing |
|---|---|---|
| Necrotizing fasciitis | Surgical debridement |
Immediate (within hours)
|
| Perforated viscus | Surgical repair |
Emergent (within 6 hrs)
|
| Ascending cholangitis | ERCP / Cholecystostomy |
Urgent (within 6-12 hrs)
|
| Obstructed pyelonephritis | Nephrostomy / Ureteric stent |
Urgent
|
| Abscess (any site) | Drainage (percutaneous or surgical) |
Within 12 hrs
|
| Infected device/catheter | Remove device |
Immediate
|
| Empyema | Chest tube drainage |
Urgent
|
| SpO₂ | Intervention |
|---|---|
|
94-98%
|
Target; no O₂ if achieved |
|
90-94%
|
Nasal cannula or mask |
|
< 90% on mask
|
HFNC or NIV |
|
Failure of NIV or GCS < 8
|
Intubation |
| Parameter | Target |
|---|---|
| Tidal Volume |
6 mL/kg PBW
|
| Plateau Pressure |
< 30 cm H₂O
|
| PEEP |
Per ARDSNet table
|
| FiO₂ |
Titrate to SpO₂ 92-96%
|
| Indication for RRT |
|---|
| Refractory hyperkalemia (K > 6.5 mEq/L) |
| Refractory acidosis (pH < 7.1) |
| Refractory fluid overload |
| Uremic complications |
| Severe AKI with oliguria |
| Agent | Dose |
|---|---|
| Enoxaparin |
40 mg SC OD
|
| UFH |
5000 U SC BD/TID
|
| IPC |
If anticoagulation contraindicated
|
| Indication | Agent |
|---|---|
| Mechanically ventilated > 48 hrs | Pantoprazole 40 mg IV OD |
| Coagulopathy | Pantoprazole 40 mg IV OD |
| Timing | Route |
|---|---|
| Within 24-48 hrs | Enteral nutrition (preferred) |
| Target | 20-25 kcal/kg/day; Protein 1.2-2 g/kg/day |
| Drug | Dose |
|---|---|
| Fentanyl |
25-100 μg/hr
|
| Propofol |
5-50 μg/kg/min
|
| Dexmedetomidine |
0.2-1.4 μg/kg/hr
|
| Parameter | Frequency | Target |
|---|---|---|
| MAP |
Continuous
|
≥ 65 mmHg
|
| Urine output |
Hourly
|
> 0.5 mL/kg/hr
|
| Lactate |
q2-6h
|
Decreasing; < 2 mmol/L
|
| SpO₂ |
Continuous
|
92-96%
|
| Blood glucose |
q1-4h
|
140-180 mg/dL
|
| Temperature |
q4h
|
36-38°C
|
| Parameter | Sign |
|---|---|
| MAP | ≥ 65 without increasing vasopressors |
| Lactate | Decreasing > 10% every 2-4 hrs |
| Urine output | Improving |
| Mental status | Improving |
| Vasopressor requirement | Decreasing |
| Criterion | Met? |
|---|---|
| Hemodynamically stable without vasopressors > 24 hrs |
☐
|
| Adequate oxygenation on ≤ 6 L/min O₂ |
☐
|
| Lactate normalized |
☐
|
| Source controlled |
☐
|
| Antibiotic course defined |
☐
|
| Mental status stable |
☐
|
| Tolerating enteral nutrition |
☐
|
| Element | Done? |
|---|---|
| Measure lactate |
☐
|
| Blood cultures |
☐
|
|
Broad-spectrum antibiotics
|
☐
|
| 30 mL/kg crystalloid |
☐
|
| Vasopressors if MAP < 65 |
☐
|
| Source | Give |
|---|---|
|
Unknown
|
Ceftriaxone 2g IV + Metronidazole 500mg IV |
|
Chest
|
Ceftriaxone 2g IV + Azithromycin 500mg IV |
|
Urine
|
Ceftriaxone 2g IV |
|
Abdomen
|
Ceftriaxone 2g IV + Metronidazole 500mg IV |
|
Skin
|
Ceftriaxone 2g IV + Clindamycin 600mg IV |
|
Meningitis
|
Ceftriaxone 2g IV STAT |
|
Scrub Typhus
|
Doxycycline 100mg IV/PO |
| Drug | Start | Max |
|---|---|---|
|
Norepinephrine
|
0.1 μg/kg/min
|
1-2+ μg/kg/min
|
|
Vasopressin
|
0.03 U/min
|
0.04 U/min
|
|
Epinephrine
|
0.05 μg/kg/min
|
1 μg/kg/min
|
| ⛔ NEVER | ✅ ALWAYS |
|---|---|
| Delay antibiotics for cultures |
Antibiotics within 1 hour
|
| Use fluoroquinolones empirically for UTI in India | Use Pip-Taz or Carbapenem for serious UTI |
| Use dopamine first-line | Use Norepinephrine first-line |
| Give steroids for all sepsis | Steroids only for refractory shock |
| Use HES (colloids) | Use crystalloids (RL preferred) |
| Forget tropical infections | Consider Scrub Typhus, Malaria, Dengue, Leptospirosis |
| Miss source control | Identify and control source urgently |
| Situation | Remember |
|---|---|
| Fever with eschar | Scrub Typhus → Doxycycline |
| Fever + splenomegaly | Rule out Malaria, Enteric fever, Kala-azar |
| Monsoon/post-monsoon fever | Consider Leptospirosis, Scrub Typhus, Dengue |
| Severe UTI | Assume ESBL → Pip-Taz or Carbapenem |
| ICU-acquired GNB infection | Assume MDR/CRE → Colistin-based regimen |
| High FQ resistance | Don't use Ciprofloxacin/Levofloxacin empirically for UTI or enteric fever |
| Abbreviation | Full Form |
|---|---|
|
SIRS
|
Systemic Inflammatory Response Syndrome |
|
SOFA
|
Sequential Organ Failure Assessment |
|
qSOFA
|
Quick SOFA |
|
MAP
|
Mean Arterial Pressure |
|
ESBL
|
Extended-Spectrum Beta-Lactamase |
|
CRE
|
Carbapenem-Resistant Enterobacteriaceae |
|
MDR
|
Multi-Drug Resistant |
|
MRSA
|
Methicillin-Resistant Staphylococcus aureus |
|
VRE
|
Vancomycin-Resistant Enterococcus |
|
GNB
|
Gram-Negative Bacteria |
|
CAP
|
Community-Acquired Pneumonia |
|
HAP
|
Hospital-Acquired Pneumonia |
|
VAP
|
Ventilator-Associated Pneumonia |
|
UTI
|
Urinary Tract Infection |
|
BSI
|
Bloodstream Infection |
|
CoNS
|
Coagulase-Negative Staphylococcus |
|
ATT
|
Anti-Tubercular Therapy |
|
ACT
|
Artemisinin-based Combination Therapy |
|
CRRT
|
Continuous Renal Replacement Therapy |
|
ARDS
|
Acute Respiratory Distress Syndrome |
|
HFNC
|
High-Flow Nasal Cannula |
|
NIV
|
Non-Invasive Ventilation |
|
IPC
|
Intermittent Pneumatic Compression |
|
DVT
|
Deep Vein Thrombosis |
|
PBW
|
Predicted Body Weight |
|
RBS
|
Random Blood Sugar |
|
POC
|
Point of Care |
|
RL
|
Ringer's Lactate |
|
NS
|
Normal Saline |
|
NE
|
Norepinephrine |
|
FQ
|
Fluoroquinolone |
|
Pip-Taz
|
Piperacillin-Tazobactam |
|
TMP-SMX
|
Trimethoprim-Sulfamethoxazole |
|
MU
|
Million Units |
| Guideline/Source | Year |
|---|---|
| Surviving Sepsis Campaign Guidelines | 2021 |
| Surviving Sepsis Campaign Update | 2024 |
| ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes | 2019 |
| ICMR Antimicrobial Resistance Surveillance Report | 2022 |
| IDSA Clinical Practice Guidelines (various) |
Various
|
| Indian Society of Critical Care Medicine (ISCCM) Guidelines |
Various
|
| API Textbook of Medicine |
Latest Edition
|
| National CDC India Guidelines |
Current
|
| UK Sepsis Trust – Sepsis Six |
Current
|
Medical Advisory
Clinical guidelines are subject to change. Physicians should exercise their regular clinical judgment. This protocol does not replace individual institutional policies. Verified for Q1 2026.
Help us improve our clinical database for the medical community.